Prothionamide Dose Optimization Using Population Pharmacokinetics for Multidrug-Resistant Tuberculosis Patients-Reference-Cited by-同舟云学术

Prothionamide Dose Optimization Using Population Pharmacokinetics for Multidrug-Resistant Tuberculosis Patients

Published:2022-09-20 Issue:9 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Yun Hwi-yeol¹,Chang Min Jung²³⁴^ORCID,Jung Heeyoon⁵,Chang Vincent⁶,Wang Qianwen⁶,Strydom Natasha⁶^ORCID,Yoon Young-Ran⁷⁸^ORCID,Savic Radojka M.⁶^ORCID

Affiliation:

1. Department of Pharmacy, College of Pharmacy, Chungnam National University, Daejeon, Republic of Korea

2. Department of Pharmacy and Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, Republic of Korea

3. Department of Pharmaceutical Medicine and Regulatory Science, Yonsei University, Incheon, Republic of Korea

4. Graduate Program of Industrial Pharmaceutical Science, Yonsei University, Incheon, Republic of Korea

5. Department of Bio-AI Convergence, Chungnam National University, Daejeon, Republic of Korea

6. Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA

7. Department of Molecular Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea

8. Department of Clinical Pharmacology, Kyungpook National University Hospital, Daegu, Republic of Korea

Abstract

Prothionamide, a second-line drug for multidrug-resistant tuberculosis (MDR-TB), has been in use for a few decades. However, its pharmacokinetic (PK) profile remains unclear.

Funder

Chungnam National University

MSIT | Institute for Information and Communications Technology Promotion

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.01893-21

Reference25 articles.

1. World Health Organization. 2020. Global tuberculosis report 2020. World Health Organization, Geneva, Switzerland.

2. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline

3. World Health Organization. 2019. Consolidated guidelines on tuberculosis. World Health Organization, Geneva, Switzerland.

4. Recent advances in the design of inhibitors of mycobacterial transcriptional regulators to boost thioamides anti-tubercular activity and circumvent acquired-resistance

5. Plasma levels of ethionamide and prothionamide in a volunteer following intravenous and oral dosages

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent efforts in the development of glycoconjugate vaccine and available treatment for tuberculosis;Bioorganic Chemistry;2024-09

2. Advanced drug delivery and therapeutic strategies for tuberculosis treatment;Journal of Nanobiotechnology;2023-11-09

3. Tuberculosis of the spine;World Journal of Orthopedics;2023-05-18